BioSpace News Archive

Jaya Biosciences, Inc. reported preclinical data at the 45th Annual Meeting of the Society for Inherited Metabolic Disorders, a leading research conference on inherited metabolic diseases, including lysosomal diseases.

IGC Pharma, Inc. (“IGC Pharma,” “IGC,” or the “Company”) (NYSE American: IGC) today announced that interim data from its Phase 2 clinical trial demonstrates a clinically significant reduction, approaching statistical significance, in agitation in Alzheimer’s at week two compared to placebo.

AmplifyBio, a Contract Development and Manufacturing Organization (CDMO) and Contract Research Organization (CRO) focused on differentiating services that cover target optimization, preclinical safety studies, and manufacturing scale-up, and RNAV8 Bio, an emerging startup focused on mRNA engineering platforms, are partnering to provide a one-stop shop for the development of mRNA therapeutics.

Cardiawave SA, a French Medtech company that has developed an innovative Non-Invasive Ultrasound Therapy (NIUT) device for the treatment of severe symptomatic calcific aortic stenosis, is delighted to announce the appointment of Olivier Pierron as its new Chief Executive Officer.

Olympus announced positive changes to commercial payer policies covering patients who could benefit from the iTind™ procedure, a minimally invasive treatment for the lower urinary tract symptoms caused by benign prostatic hyperplasia, also known as enlarged prostate.

The Board of Directors of the Kaiser Permanente Bernard J. Tyson School of Medicine announced the appointment of physician, educator, and women’s health expert John L. Dalrymple, MD, as the school’s new Dean and CEO after an extensive national search.

BioHarvest Sciences Inc. (CSE: BHSC) (OTCQB: CNVCF) (“BioHarvest” or the “Company”), a biotechnology company pioneering its patented Botanical Synthesis technology process

According to Precedence Research, the global agricultural biotechnology market was evaluated at USD 115.26 billion in 2023

In October of 2023, the US FDA approved Novartis’ intravenous formulation of Cosentyx for the treatment of psoriatic arthritis, ankylosing spondylitis and non-radiographic axial spondyloarthritis.

IN8bio, Inc. (Nasdaq: INAB) a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today announced that William Ho, CEO and Co-founder, will present at the Noble Capital Markets’ Emerging Growth Virtual Healthcare Equity Conference on Thursday, April 18th at 12:30pm ET.